Publicaciones en las que colabora con JUAN JOSÉ TORRADO DURÁN (22)

2023

  1. Targeting lung macrophages for fungal and parasitic pulmonary infections with innovative amphotericin B dry powder inhalers

    International journal of pharmaceutics, Vol. 635, pp. 122788

2020

  1. Evaluating the potential of ursolic acid as bioproduct for cutaneous and visceral leishmaniasis

    Molecules, Vol. 25, Núm. 6

2017

  1. Engineering oral and parenteral amorphous amphotericin B formulations against experimental Trypanosoma cruzi infections

    Molecular Pharmaceutics, Vol. 14, Núm. 4, pp. 1095-1106

2015

  1. Oral particle uptake and organ targeting drives the activity of amphotericin B nanoparticles

    Molecular Pharmaceutics, Vol. 12, Núm. 2, pp. 420-431

2014

  1. New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp

    International Journal of Pharmaceutics, Vol. 473, Núm. 1-2, pp. 148-157

2013

  1. Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations

    International Journal of Pharmaceutics, Vol. 447, Núm. 1-2, pp. 38-46

2012

  1. Enantiomerical pharmacokinetic prevalence of (+) albendazole sulphoxide in Trichinella spiralis muscle larvae

    Parasitology Research, Vol. 110, Núm. 2, pp. 993-999

2009

  1. The effect of intestinal trichinellosis on oral bioavailability of albendazole in mice

    Parasitology Research, Vol. 105, Núm. 1, pp. 65-70

2008

  1. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation

    Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 5, pp. 1125-1131

2007

  1. In vitro effect of new formulations of amphotericin B on amastigote and promastigote forms of Leishmania infantum

    International Journal of Antimicrobial Agents, Vol. 30, Núm. 4, pp. 325-329

2006

  1. Real-time reverse transcription-PCR quantification of cytokine mRNA expression in golden Syrian hamster infected with Leishmania infantum and treated with a new amphotericin B formulation

    Antimicrobial Agents and Chemotherapy, Vol. 50, Núm. 4, pp. 1195-1201

2005

  1. Influence of the vehicle on the properties and efficacy of microparticles containing amphotericin B

    Journal of Drug Targeting, Vol. 13, Núm. 4, pp. 225-233

2004

  1. Amphotericin B molecular organization as an essential factor to improve activity/toxicity ratio in the treatment of visceral leishmaniasis

    Journal of Drug Targeting, Vol. 12, Núm. 7, pp. 453-460

  2. Anti-leishmanial activity of a new formulation of amphotericin B

    Tropical Medicine and International Health, Vol. 9, Núm. 9, pp. 981-990

  3. Ex Vivo Anthelmintic Activity of Albendazole-Sulphoxide Enantiomers

    Journal of Parasitology, Vol. 90, Núm. 2, pp. 407-409

  4. Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres

    Antimicrobial Agents and Chemotherapy, Vol. 48, Núm. 9, pp. 3246-3252

2003

  1. Bioavailability and efficacy characteristics of two different oral liquid formulations of albendazole

    International Journal of Pharmaceutics, Vol. 250, Núm. 2, pp. 351-358

2001

  1. Improving bioavailability and anthelmintic activity of albendazole by preparing albendazole-cyclodextrin complexes

    Parasite, Vol. 8, pp. S188-S190

1999

  1. Preparation and characterization of albendazole β-cyclodextrin complexes

    Drug Development and Industrial Pharmacy, Vol. 25, Núm. 12, pp. 1241-1248

  2. Quantitative determination of albendazole and its main metabolites in plasma

    Journal of Chromatography B: Biomedical Sciences and Applications, Vol. 723, Núm. 1-2, pp. 265-271